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The Legal Aspects of Chemical
Restraint Use in Nursing Homes
Chemical restraint, the excessive con-
trol of behavior by the use of medica-
tion, is just one of the many risks faced
by the residents of nursing homes. This
article explores the definition of chemi-
cal restraint, its adverse effect, relevant
federal and state laws and regulation,
customary industry practice, and prac-
tice tips for correcting discovered
abuse.
By Julie A. Braun and
Lawrence A. Frolik
Julie A. Braun, J.D., L.L.M. is a Chicago-based health
law attorney and writer. She is Co-Chair Elect of the
American Bar Association Torts and Insurance Practice
Section Medicine and Law Committee and former Vice
Chair of its Seniors' Law Committee. She teaches,
writes, and lectures nationally on health law subjects.
Lawrence A. Frolik is a Professor of Law at the
University of Pittsburgh School of Law. He is the co-
author (with M. Brown) of Advising the Elderly or
Disabled Client (2d ed., Warren Gorham & Lamont),
Residence Options for the Older or Disabled Client
(Warren Gorham & Lamont), and Aging and the Law:
An Interdisciplinary Reader (Temple University Press).
he 1.6 million people who live in the
nation's nursing homes are a highly vul-
nerable population. Among the risks
faced by nursing home residents are
excessive behavior control and restraint
by the use of medication, commonly referred to as
chemical restraint. "[M]edication, when used judi-
ciously, can be a valuable adjunct in maximizing
function and maintaining well-being in elderly
nursing home residents. When used inappropriate-
ly, [it] can be an instrument of harm, abuse, negli-
gence and malpractice."' Of course, drugs are used
for a variety of purposes and may have a positive
value as part of a well-planned therapeutic strategy.
For example, absent treatment, severe depression
can lead to suicide or indirect life-threatening
behavior such as a failure to eat. Too often, how-
ever, drugs are used without adequate monitoring
for harmful side effects, or even worse, are used to
restrain rather than help the resident. Moreover,
many, if not most, residents take multiple drugs, a
practice known as polypharmacy.2 How many is
too many? While no precise guidelines exist, it is
known that as the number of prescription drugs
increases, the likelihood of drug interactions, toxi-
city, and side effects increases exponentially for the
older adult.' Five drugs or more in a treatment reg-
imen arouses concern; ten or more sharply increas-
es the likelihood that the resident will experience
deleterious side effects. 4
What Are Chemical Restraints?
Chemical restraints include "any drug that is used
for discipline or convenience and not required to
treat medical symptoms."' Interestingly, this defin-
ition no longer singles out psychopharmacological
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drugs.6 Removing the term psychopharmacological
from the standard acknowledges that a wide range
of drugs may be used as chemical restraints.
Discipline means "any action taken by the facility
for the purpose of punishing or penalizing resi-
dents." 7 Convenience involves actions taken by the
facility to reduce its burdens rather than to pro-
mote the best interest of the resident
Older nursing home residents who suffer from
mental disability are often prescribed psychotropic
medications. Commonly prescribed psychotropic9
medications appear in Table 1 0 This list is not
exhaustive; new drugs continue to be developed
and employed.
Adverse Effects of Chemical Restraint
When used properly, psychotropic drugs can be an
important treatment therapy. Unfortunately, such
drugs can also be used to control or chemically
restrain residents who would otherwise pose
behavioral problems. A growing awareness of the
risk of chemical restraint has led to an examination
and reevaluation of drug use in long-term care
facilities. (Even drugs prescribed for medically
sound reasons may have harmful side effects par-
ticularly when they interact and when used with
over-the-counter drugs.)
Aging affects how the body handles a drug (that
is, movement into, around, and out of the body) as
well as the specific action of the drug itself on the
older person's body. A review of nineteen clinical
studies concluded that a substantial number of
nursing home residents who were taking psy-
chotropic drugs on a regular, long-term basis suf-
fered harmful side effects." A 1997 report released
by the Office of Inspector General Department of
Health and Human Services arrived at a similar
conclusion.' 2 Numerous drugs and drug combina-
tions place persons over the age of sixty-five at
greater risk of adverse drug outcomes.13
Not surprisingly, overuse of drugs erodes the
resident's autonomy. Overdrugged residents may
not speak or think clearly and exhibit less interest
in self-care. Other consequences of over-reliance on
drugs or the resort to chemical restraint include the
risks presented in Table 2."
Table 1. Psychotropic Medications (generic name followed by brand name in parentheses)
Antidepressant Medications
Imipramine (Tofranil)
Desipramine (Norpramin)
Doxepin (Adapin, Sinequan)
Nortriptyline (Aventyl, Pamelor)
Fluoxetine (Prozac)
Sertraline (Zoloft)
Trazodone (Desyrel)
Antipsychotic Medications
Haloperidol (Haldol)
Thioridazine (Mellaril)
Thiothixene (Navane)
Chlorpromazine (Thorazine)
Risperidone (Risperdal)
Olanzapine (Zyprexa)
Mood Stabilizers
Lithium carbonate (several brands)
Valproic acid (Depakene)
Anxiolytic Medications
(counteract or diminish anxiety)*
Oxazepam (Serax)
Alprazolam (Xanax)
Diazepam (Valium)
Lorazepam (Ativan)
Diphenhydramine (Benadryl)
Hydroxyzine (Atarax, Vistaril)
Buspirone (BuSpar)
Sedative-Hypnotic Medications**
(sleep inducers)
Flurazepam (Dalmane)
Temazepam (Restoril)
Lorazepam (Ativan)
Oxazepam (Serax)
Diphenhydramine (Benadryl)
Hydroxyzine (Atarax, Vistaril)
Chloral hydrate (several brands)
* TABER'S CYCLOPEDIC MEDICAL DICTIONARY, 129 (17th ed. 1993) (defining anxiolytic).
* Id. at 944, 1773 (defining hypnotics and sedative, respectively).
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Table 2. Consequences of Chemical Restraint
* Agitation e Functional decline
* Gait disturbance 9 Increased fall risk
* Memory impairment o Movement disorders
* Sedation * Orthostatic/Postural
* Withdrawal hypotension
Increased Fall Risk
"An increase in body sway or unsteadiness has
been demonstrated shortly after the administration
of psychotropic medications" in the older adult.'5
Any drug that interferes with the resident's postur-
al control, cerebral perfusion, or cognitive function
may potentially influence a resident's gait and bal-
ance and induce a fall. 6 Injuries suffered as a result
of the fall may lead to further decline. 17
Orthostatic/Postural Hypotensionm
Medications with anticholinergic" properties (for
example, tricyclic antidepressant drug therapy) may
cause a drop in blood pressure when the patient
attempts to stand. This may result in dizziness,
fainting, falls, and even heart attack or stroke.2"
Sedation
Older residents are more vulnerable to the common
side effects of psychotropic medication, such as
sedation, and may experience drowsiness or
decreased consciousness. Families who find a rela-
tive unresponsive or difficult to wake should inves-
tigate whether staff members are using drugs mere-
ly to make the resident more quiescent and easier
to care for. If so, there may be grounds for a suc-
cessful lawsuit.
Movement Disorders
Some psychotropic drugs cause a complete or par-
tial loss of muscle movement that markedly
decreases body activity (akinesia);21 motor restless-
ness-an inability to sit still (akathisia);22 muscle
spasms of the eye, neck, and back (dystonias);23
stiffness, rigidity, tremor, and drooling (symptoms
resembling Parkinson's disease);2 4 and slow, rhyth-
mical, involuntary, repetitive, purposeless move-
ments involving the eyes, face, mouth, tongue,
trunk, and limbs (tardive dyskinesia).25
Memory Impairment
Psychotropic medications may cause the patient to
become confused, disoriented, or suffer amnesia.
Functional Decline
Many residents who receive psychotropic drugs
suffer functional decline in activities of daily living
such as eating, walking, dressing, using a wheel-
chair, or using the restroom. If the decline is not
reversed, the resident is at risk of malnutrition,
contractures, aspiration pneumonia, and pressure
sores.
26
Agitation
Sedative or hypnotic drugs may cause some
patients to become agitated, experience insomnia,
hallucinations, nightmares, and become hostile or
even violent.
Withdrawal
Even taking the resident off the drugs can be prob-
lematic. Many residents suffer severe physical or
psychological withdrawal symptoms. To avoid
these and other harmful effects, drugs must be care-
fully prescribed and monitored. Any side effects
must be documented, and the resident's behavior
monitored.
Federal Law and Regulation
For years nursing homes felt free to use drugs as a
form of chemical restraint.27 This pattern of prac-
tice changed dramatically with the passage of the
landmark nursing home reforms contained within
the Omnibus Budget Reconciliation Act of 1987
(OBRA '87).28 The OBRA '87 contains the Nursing
Home Bill of Rights29 that applies to residents of
facilities certified for participation in the Medicare
and Medicaid programs, the primary funders of
long-term care.3" (Implementing regulations appear
in Title 42 of the Code of Federal Regulations.31)
The Health Care Financing Administration
(HCFA), within the Department of Health and
Human Services is responsible for ensuring the
quality of nursing homes as part of its oversight of
the Medicare and Medicaid programs.
Government surveyors rely on HCFA guidelines,
which are periodically updated, when they evaluate
compliance with, among other things, the appro-
priateness of chemical restraint.
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Freedom from Chemical Restraint
The Nursing Home Bill of Rights specifically states
that nursing home residents have "the right to be
free from physical or mental abuse, corporal pun-
ishment, involuntary seclusion, and any physical or
chemical restraints imposed for purposes of disci-
pline or convenience, and not required to treat the
resident's medical symptoms."32 The statute further
states that "physical or chemical restraints may
only be imposed.. .to ensure the physical safety of
the resident or other residents."
33
Interdisciplinary Approach to Resident Care
Under federal law each resident must receive the
care needed to "attain or maintain the highest prac-
ticable physical, mental, and psychosocial well-
being." 34 A nursing home is required to create a
comprehensive interdisciplinary clinical evaluation
and care plan that demonstrates how it expects to
assist the resident in reaching his or her highest
level of well-being.3" An interdisciplinary geriatric
team may consist of a physician, nurse, pharmacist,
activities therapist, occupational and physical ther-
apists, speech and language pathologist, or a social
worker.36 The team creates a care plan, which might
include the use of drugs. If, however, the plan does
not, any use of drugs represents an unacceptable
and illegal form of control or restraint.
The Need for Informed Consent
Even if the care plan recommends the use of drugs,
the resident must consent to such use. Residents, or
their legal health care decision-makers, must give
informed consent before they are given drugs for
any purpose, including as a device to control
behavior.37 The risks, benefits, and alternatives to
restraint must be explained in the context of the
resident's condition, circumstances, and environ-
ment. The resident has the right to refuse or accept
chemical restraint38 even if the resident's physician
recommends the medication, or the facility claims
that without it the resident is too difficult to man-
age.39 Significantly, a resident's refusal does not
absolve the facility from providing care that allows
the resident to attain or maintain the highest prac-
ticable physical, mental, or psychosocial well-
being.
When a resident is incapable of making an
informed decision, the resident's legal surrogate or
representative may exercise the right based on the
same information that would have been provided
to the resident. ° However, the legal surrogate or
representative cannot give permission to use chem-
ical restraints for discipline or staff convenience or
when the restraint is not necessary to treat the res-
ident's medical symptoms." Residents can state in
their advance health care directives their prefer-
ences concerning chemical restraint use.42
Physician Order Required
Assuming that proper informed consent to the use
of a drug has been obtained, it can be used "only
upon the written order of a physician that specifies
the duration and circumstances under which the
restraints are to be used."43 The physician's order
will appear directly in the nursing home resident's
record or as a telephone order later signed by the
physician. In an emergency, however, chemical
restraints may be used without a physician's order
unless the nursing home has been previously noti-
fied that such treatment is not acceptable.44
Federal Law Prohibits Unnecessary Drugs
Federal law requires that "[e]ach resident's drug
regimen must be free from unnecessary drugs. " "
According to federal regulations, an unnecessary
drug is any drug used:46
" in excessive dosage, including duplicate drug
therapy;
" for excessive duration;
" without adequate monitoring;
" without adequate indications for its use;
" in the presence of adverse consequences which
indicate that use of the drug should be
reduced or discontinued; or
" any combination of the reasons above.4
Check the surveyor's guidelines interpreting the
federal regulations for acceptable dosages for spe-
cific medications. For example, daily use is equal to
or less than 7.5 mg by mouth for temazepam
(Restoril), a drug for sleep induction, unless higher
doses (as evidenced by the resident's response
and/or clinical record) are necessary for mainte-
nance or improvement in the resident's functional
status.48
Although the federal guidelines do not create a
private right of action, there have been successful
civil suits for damages caused by excessive drug
use. For example, a $908,800 settlement was
reached in a case involving a sixty-one-year-old
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nursing home resident who was given too much
Lithium, a drug with a narrow safety margin. 9 The
plaintiff claimed that excessive doses of Lithium
were given over a three-week period, resulting in
acute Lithium toxicity and cognitive brain dam-
age.50
Gradual Dose Reduction
If the resident is a victim of chemical restraint, the
reduction of drug dosages must be carefully moni-
tored. There should be a systematic and gradual
process of reducing or discontinuing the drugs that
follow a physician-approved care plan.' "Gradual
dosage reductions consist of tapering the resident's
daily dosage to determine whether the resident's
symptoms can be controlled by a lower dose or if
the drug can be eliminated altogether." 2 Federal
regulatory guidelines identify time periods within
which gradual dose reduction should be attempted.
For example, a gradual dose reduction should be
attempted at least twice within one year for benzo-
diazepines.53 For drugs in the sedative-hypnotic
class, a gradual dose reduction is recommended at
least three times within six months before conclud-
ing that a gradual dose reduction is clinically con-
traindicated s4 Antipsychotic and antidepressant
medications require gradual dose reduction, but no
time period is suggested.5
Response to Federal Law and Regulation
Thanks to federal and state regulations, there
appears to be a reduction in the use of chemical
restraints in nursing homes.5 6 Clinicians report
that OBRA '87 mandates regarding drug usage
have increased awareness of chemical restraint 7
and have significantly reduced the excessive use of
drugs in nursing homes.5s Still, resident advocacy
groups, such as the National Citizens' Coalition
for Nursing Home Reform, claim that the use of
psychotropic medication remains unnecessarily
high.5 9
State Law and Regulation
Virtually every state regulates restraint use in nurs-
ing homes. For example, Arkansas law prohibits
chemical restraint unless authorized by a physician
for a specified time period or needed for an emer-
gency.6 Residents injured by a facility's violation of
this law may sue to recover actual and punitive
damages, but the court cannot award attorneys'
fees.61 Colorado law limits chemical restraint to
instances when there is an emergency and no less
restrictive alternatives are available or appropri-
ate.62 New York law requires the following con-
trols:
" psychotropic drugs must not be used for disci-
pline or convenience;
" psychotropic drugs must be ordered only by a
physician who specifies the problem for which
the drug is prescribed;
" psychotropic drugs may be used only as an
integral part of the resident's comprehensive
care plan and only after alternative methods
of treating the resident's condition or symp-
toms have been tried and have failed;
" efforts must be made to discontinue psy-
chotropic drug use through gradual dose
reductions and behavioral interventions; and
" psychotropic drug use must be discontinued if
the harmful effects outweigh the benefits of
the drug.63
Customary Industry Practice
Nursing home risk managers and attorneys han-
dling or defending chemical restraint cases may
find it useful to compare the frequency of chemical
restraint use in the facility in question with that of
other nursing homes. The customary industry prac-
tice, in part, establishes the legal standard of care.
Major Organizational Positions on Chemical
Restraints
When determining what constitutes unnecessary
use of drugs, courts naturally rely on relevant gov-
ernment statutes and regulations as well as cus-
tomary industry practice. They also look to major
organizational policy statements regarding chemi-
cal restraint use as evidence of what is the appro-
priate standard of care. The American Association
for Geriatric Psychiatry and the American
Geriatrics Society have issued statements on the use
of psychotherapeutic medications in nursing
homes.' Both organizations "emphasize the impor-
tance of distinguishing between the appropriate use
of psychoactive medications and their misuse."65 In
addition, the American Health Care Association,
representing more than 10,500 nursing homes, has
adopted a set of practice guidelines to reduce
antipsychotic medication use in long-term care
facilities."6
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Voluntary Accreditation Standards
The accreditation process also plays an important
role in determining industry standards. The Joint
Commission on Accreditation of Healthcare
Organizations (JCAHO) 1998-1999 Compre-
hensive Accreditation Manual for Long-Term Care
includes standards for chemical restraint use. 7 The
standards focus on individual resident needs and
individualized assessment. 68 The legal significance
of JCAHO standards lies in their admissibility as
evidence of the acceptable tort standard of care.69
Hypothetical Chemical Restraint Case
The difference between drug use as a form of chem-
ical restraint versus appropriate therapy is demon-
strated in the following hypothetical. °
Facts
Ann Jones, an eighty-five-year-old female with
dementia, is confined to a wheelchair because of
severe arthritis and the amputation of her right foot
from complications of diabetes. In the last few
weeks she has begun to scream, curse, and grab at
staff and visitors. During mealtimes she takes other
residents' food and casts her own food off the
table. All agree that Ann's behavior is unacceptable
and requires the use of a behavior-altering drug.
Solution A
Ann's new care plan includes pain management
and dietary assessment for food preferences and
adequacy of portions. Different behavioral strate-
gies are initiated, including increased socialization.
Alternate feeding strategies were tried for Ann,
including a change in her feeding environment and
the type of food offered. After these behavior and
feeding strategies proved ineffective, her physician
prescribed low doses of Haldol (0.5 milligrams
every eight hours). The result was decreased agita-
tion, more cooperation about eating, and less dis-
ruption at meals.
Solution B
The facility isolated Ann in her room where she
continued to scream loudly. She ate alone and
threw her food on the floor. The staff complained
to her physician, describing Ann as an uncoopera-
tive nuisance in need of calming down. The physi-
cian responded by ordering Haldol (1.0 milligrams
every six hours) plus Ativan (2 milligrams every six
hours) as needed. The result was that Ann became
a quiet, sleeping, drooling resident in a wheelchair.
Analysis
In Solution A, the prescribed medication was not
used as a chemical restraint because it was appro-
priately integrated with behavioral and feeding
strategies. Most importantly, the dosage of the
medication was not excessive. Only enough was
prescribed to calm Ann, but not enough to sedate
her.
In sharp contrast, Solution B demonstrates
inappropriate chemical restraint use (in violation of
42 C.ER. S 483.13(a)). The medication regimen
constituted unnecessary drug therapy (in violation
of 42 C.ER. S 483.25(l)(1)). No behavioral inter-
ventions were attempted (in violation of 42 C.ER.
483.25(1)(2)(ii)). In addition, multiple medica-
tions were inappropriately administered in exces-
sive dosages without monitoring for side effects (in
violation of 42 C.ER. S 483.25(1)). The medication
was administered for staff convenience (in viola-
tion of 42 C.ER. S 483.13(a)). Moreover, Ann was
not treated with dignity (in violation of 42 C.ER.
S 483.15(a)) and was a victim of involuntary seclu-
sion (in violation of 42 C.ER. S 483.15(a)). The
physician did not appropriately monitor changes in
the resident's medical status (in violation of 42
C.F.R. S 483.40).
Practice Tips
Understanding Medical Terminology
Attorneys who represent nursing home residents
must understand medical terminology and know
how to read the nursing home record. Unless an
attorney possesses a formal education in medicine
or nursing, the terminology found in a nursing
home record can be perplexing. A medical dictio-
nary such as Taber's Cyclopedic Medical
Dictionary, Mosby's Drug Guide for Nurses, or the
Physician's Desk Reference7' can be helpful in
understanding the nursing home record, which
may differ materially in content and organization
from hospital or other medical facility records with
which the attorney may be familiar.
Examining the Nursing Home Record
Nursing home residents' medical charts vary in
length and complexity, depending upon the resi-
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dent's physical and mental health, the number of
persons involved in the resident's care and, to a cer-
tain extent, the sophistication of the facility. For
example, the level of documentation in a small,
rural nursing home may be quite different from the
documentation practices of a private, profit-mak-
ing facility owned by a national chain.
The facility is required to maintain an individ-
ual medication record for each resident.72
Medication refers to all prescription and over-the-
counter medications taken by the resident, includ-
ing dosage, frequency of administration, and
recognition of side effects likely to occur in the res-
ident. Though this information need not appear in
the resident's assessment, it must be included in the
resident's clinical record and care plan. Table 3
reflects some of the terminology typically encoun-
tered in a resident's medication record.
Whenever excessive or inappropriate drug use is
suspected, the attorney needs to inquire about what
drugs, in what strength and what dosage forms, are
being administered to the resident. The attorney
should also inquire when (such as daily or after
meals) and how (by mouth or intramuscular injec-
tion, for example) the drugs are administered. Each
facility will have a policy relative to dosing sched-
ules. Usually there is an early and late medication
pass during an eight-hour shift. The morning is
when most doses are administered in long-term
care facilities. In practice, one nurse may adminis-
ter medication for 30 or more residents in what is
referred to as the drug administration pass.
Even a careful examination of the resident's file
may not reveal chemical restraint. Often facility
practices may not be reflected in the resident's
chart, or the staff may correct the paper entry
rather than the practice. Compare family and resi-
dent observations with current signed orders for
drug use. There may be fraudulent entries and
incomplete charting. Some questions to consider
include the following:
" Did a valid order for the administered drug(s)
exist?
" Was each drug administered according to the
physician's order?
" Was each drug given in the correct strength
and by the correct method?
" Was the drug used appropriate for the resi-
dent?
" Were any blank spaces detected on the med-
ication administration record (MAR) which is
commonly kept in a notebook with the med-
ication cart for convenience in distributing
medications to the residents?
Reviewing the Nursing Home Survey
HCFA contracts with state agencies to survey nurs-
ing homes to ensure that they meet Medicare and
Medicaid participation requirements. As part of
this oversight, state agencies are required to record
any deficiencies that exist in the homes they survey.
When inspectors cite a facility for violating a spe-
cific regulation (known as an F Tag), they also rate
the scope and severity of the violation. Inspection
reports often are difficult to read and may be quite
lengthy (over 100 pages). They usually contain pro-
fessional jargon, medical terminology, and refer-
ences to nursing home standards. Yet it is impor-
tant to examine these inspection reports to deter-
Table 3. Principal Charting Terminology (medical abbreviation followed by definition)
qh every hour qod every other day subq subcutaneous
qd once a day qon every other night INJ injection
qm every morning prn as needed IM intramuscular
bid twice a day hs at bedtime C/O complains of
bin twice a night po by mouth OTC over the counter
tid 3 times a day NPO nothing by mouth Rx prescription treatment
tin 3 times a night ac before meals TO telephone order
qid 4 times a day pc after meals
qin 4 times a night subcu subcutaneous
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mine whether the facility has been cited for any
deficiencies or other violations that may relate to
suspected chemical restraints.
Facility Policy and Procedure
Evidence that written institutional policies and pro-
cedures have not been enforced is often the basis
for establishing that the standard of care has not
been met. Even if the staff follows the facility pro-
cedures, however, it is possible that the nursing
home policies and procedures are not in compli-
ance with federal and state regulations. The failure
to abide by federal or state laws may not create a
private right of action, but facility publications dis-
tributed to prospective residents or their families
may create contractual obligations that may give
rise to a cause of action based on breach of con-
tract. Examine the admissions contract to see if it
contains language about the quality of care that
may support a claim for damages. Even medical
staff bylaw provisions and facility contracts with
physicians may contain clauses that address the use
of chemical restraint.
Constructing the Event Chronology
When representing an injured or deceased nursing
home resident, it is important to appreciate the
timeline of events that precipitated the injury or
death. Cases involving chemical restraint often
unfold over weeks, months, or years, and may
involve complex events. These events may include
behavioral changes, institutional transfers, assess-
ments and reassessments, multiple injuries, and
hospitalizations. A properly constructed chronolo-
gy navigates the attorney through the discovery
process, including the formulation of deposition
questions. In addition, the medical chronology
assists throughout settlement negotiation and dur-
ing trial. A good chronology provides more than a
summary of medical care. If the case goes to trial,
a detailed chronology will introduce the jury to the
events that led to the injuries and their sequelae.
Assessing Staff Attitude, Knowledge, and
Training
Any attempt at prophylactic actions to reduce or
forestall chemical restraint must begin with staff
attitudes. The staff must be knowledgeable about
the dangers of excessive drug use. They must be
aware of when and how to administer medication
and the importance of monitoring for side effects.
Training is essential to minimizing use of chemical
restraint. The staff, from the governing board to
the nurses and nurses' aides, must receive compre-
hensive, up-to-date training regarding chemical
restraints and their alternatives. The subject should
be introduced during a new employee's orientation,
and thereafter the facility should conduct regular
staff training programs.
The American Society of Consultant Pharma-
cists, a national professional association represent-
ing more than 6,300 pharmacists who provide med-
ication distribution and consultant services to man-
age and improve drug therapy outcomes of individ-
uals residing in long-term care environments, rec-
ommends that nurses' aides receive four hours of in-
service training per year relating to medication side
effects. 3 The American Association of Homes and
Services for the Aging agrees with the need for more
education and training for all involved parties.74 The
American Medical Directors Association (AMDA),
a major association representing physicians com-
mitted to the care of nursing facility residents, pro-
vides instruction on appropriate drug use in their
program to certify long-term care medical direc-
tors. 5 The AMDA suggests that at the facility level,
surveyors, consultant pharmacists, and physicians
should be reminded of the dangers associated with
some drugs and be directed to pursue a reduction in
their use.76
Conclusion
Attorneys who represent residents of nursing
homes or the families of such residents must be
alert for drug misuse and overuse. Any suspicion of
the use of chemical restraints should be aggressive-
ly investigated, protested, and, if necessary, prose-
cuted by civil suit.
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